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Abstract 
An on-line purification and entrapment system was developed that could extract a 
protein from a sample such as serum and entrap this protein within a small column 
for use in high-performance affinity chromatography. Human serum albumin (HSA) 
was employed as a model protein for this work. Immunoextraction columns con-
taining polyclonal anti-HSA antibodies were developed to capture and isolate HSA 
from applied samples. This was followed by the use of a strong cation-exchange col-
umn to recapture and focus HSA as it eluted from the immunoextraction columns. 
The recaptured HSA was entrapped within 1.0 cm × 2.1 mm I.D. columns contain-
ing hydrazide-activated silica and in the presence of oxidized glycogen as a capping 
agent. The binding and elution properties of HSA on the various components of this 
system were examined and optimized. The entrapped columns produced by this sys-
tem were then evaluated for their use in binding studies with several sulfonylurea 
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drugs. The HSA columns created by this approach typically contained 0.3–0.6 nmol 
HSA and were stable over several weeks and more than 50–60 sample injections. 
Drug binding constants could be determined with these columns in 8 min or less 
by zonal elution and gave good agreement with literature values. The same system 
could be used for the capture and entrapment of other proteins by utilizing antibod-
ies against the given target for immunoextraction.  
Keywords: Protein immobilization, Entrapment, Immunoextraction, Human serum 
albumin, Drug-protein binding, High-performance affinity chromatography 
1. Introduction 
Human serum albumin (HSA) is the most abundant transport pro-
tein in serum, with an average physiological concentration of 42 g/L 
[1,2]. HSA has a fundamental role in the transportation of drugs and 
many other endogenous ligands in blood [1–3]. Binding to HSA can 
affect the free and active concentrations of drugs in the circulation, 
which can in turn impact a drug’s absorption, distribution, metabo-
lism, and excretion [1–4]. 
One approach that can be used to examine the binding of drugs with 
HSA is high-performance affinity chromatography (HPAC) [5,6]. HPAC 
is a technique which combines the use of an HPLC support with the 
selective and reversible interactions that can occur between a given 
analyte and an immobilized biologically-related binding agent for this 
target [6]. Columns for this method are often prepared through co-
valent immobilization of a protein such as HSA [7,8]. However, this 
type of immobilization can lead to multisite attachment or improper 
orientation of a protein and a loss of activity [7]. 
Many of these immobilization effects can be avoided by physically 
entrapping a binding agent such as a protein within a support [7,8]. 
For instance, it has been shown in recent years that this can be accom-
plished by using the reaction of aldehydes on mildly-oxidized glycogen 
with a hydrazide-activated support to entrap a soluble protein within 
HPLC-grade silica (see Fig. 1) [8]. This method has previously been 
used to immobilize HSA and other serum proteins for use in HPAC and 
drug binding studies [8–12]. Advantages of this method include the 
ability of low-to-moderate mass drugs to access the entrapped pro-
tein and for protein to remain in a soluble and fully-active form [8,9]. 
In this study, an on-line immunoextraction and entrapment system 
will be developed that can isolate a protein such as HSA from samples 
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like serum and entrap this protein within a small HPAC column (see 
Fig. 2). This system will use polyclonal anti-HSA antibodies in an im-
munoextraction column to capture and isolate HSA from an applied 
sample. A strong cation-exchange (SCX) column will be used to re-
capture and focus the HSA as this protein elutes from the immunoex-
traction column. The recaptured HSA will then be entrapped within 
a small column containing hydrazide-activated silica and in the pres-
ence of oxidized glycogen as a capping agent. The binding and elution 
properties of HSA with the immunoextraction and SCX columns will 
be examined, along with the ability of the overall system to produce 
small columns that contain entrapped HSA. The prepared columns will 
then be evaluated in drug binding studies with the entrapped HSA, 
using several sulfonylurea drugs as models [13–16]. The results that 
are obtained with HSA as a model should provide valuable guidelines 
on the use of such a system and the creation of entrapment-based col-
umns for future work with other proteins. 
2. Materials & methods 
2.1. Materials 
The polyclonal anti-HSA antibodies (goat, affinity-purified polyclonal 
antibodies, product 2080–01) were purchased from VWR (Radnor, PA, 
USA). The polyclonal anti-HSA goat serum (product A1151), protein G 
Fig. 1. Entrapment of a protein by using the coupling of oxidized glycogen with hy-
drazide-activated silica.  
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Sepharose 4B fast flow (recombinant protein expressed in E. coli), im-
munoglobulin G (IgG; goat, ≥ 95% pure), HSA (essentially fatty acid 
free, ≥ 96%), glycogen (from bovine liver, ≥ 85% glucose), oxalic di-
hydrazide (> 99%), acetohexamide (99%), glibenclamide (≥99%), 
and racemic warfarin (≥98%) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). The Nucleosil Si-300 and Si- 1000 silica (7 μm, 
particle diameter; pore size, 300 or 1000 A, respectively) were ac-
quired from Macherey-Nagel (Duren, Germany). All buffers and aque-
ous solutions were prepared using water from a Milli-Q Advantage 
10 A Water system and were filtered using 0.2 μm nylon membranes 
(EMD Millipore, Billerica, MA, USA). 
Fig. 2. General design of the on-line immunoextraction/ entrapment system. The 
injection buffer used for the immunoextraction column was pH 7.4, 0.067 M potas-
sium phosphate buffer, and the elution buffer was pH 2.5, 0.10 M potassium phos-
phate buffer. For the strong cation exchange (SCX) column, the elution buffer was 
pH 6.0, 0.10 M potassium phosphate buffer. The elution of HSA from each column 
was monitored at 280 nm. The isolated HSA was passed through a 1.0 cm × 2.1 mm 
I.D. hydrazide-activated silica column at pH 6.0 and entrapped in the presence of 
oxidized glycogen.  
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2.2. Instrumentation 
The immunoextraction/entrapment system was developed using a 
Jasco 2000 series HPLC system (Tokyo, Japan) and two Harvard ap-
paratus PHD Ultra syringe pumps (Hilston, MA, USA). The compo-
nents of the Jasco system were as follows: three PU-2080 pumps, an 
AS-2057 autosampler, a DG-2080–53 degasser, a CO-2067 column 
oven, a LV- 2080–03 solvent selector and two UV-2075 Plus absor-
bance detectors. This HPLC system also employed three Rheodyne 
Advantage PF six-port valves (Cotati, CA, USA), which were used to 
alternate the flow and application of buffers to the columns of this 
system (see Supplemental Material). The HPLC/syringe pump sys-
tem was operated using LC-Net and ChromNav V 1.18 software from 
Jasco. Chromatograms were analyzed by using PeakFit 4.12 soft-
ware from Jandel Scientific (San Rafael, CA, USA) and Microsoft Ex-
cel 2016 (Redmond, WA, USA). Ultrafiltration and buffer exchange 
were carried out by using VivaSpin 6 ultrafiltration spin columns (30 
kDa) from Sartorious Stedim (Gottingen, Germany) and a 5702RH 
temperature-controlled centrifuge (Eppendorf, New York, NY, USA). 
The centrifuge was operated at 3000 rpm and 25 °C in most cases 
except during the purification of oxidized glycogen, when the tem-
perature was 37 °C. 
2.3. Development of immunoextraction columns 
The anti-HSA immunoextraction columns were prepared by using af-
finity-purified polyclonal anti-HSA antibodies or anti-HSA goat serum. 
The affinity-purified anti-HSA antibodies were immobilized onto Nu-
cleosil-1000 silica via the Schiff base method, as previously described 
[17]. A control support was developed in the same manner but in the 
absence of antibodies. Prior to immobilization, the buffer in which the 
anti-HSA antibodies were supplied was exchanged by ultrafiltration, 
with the antibodies being placed into pH 6.0, 0.10 M potassium phos-
phate buffer. The protein content of the anti-HSA support was deter-
mined in triplicate by utilizing a micro bicinchoninic acid (BCA) pro-
tein assay kit obtained from Thermo Fisher Scientific (Waltham, MA, 
USA). In this assay, goat IgG was used as the standard and the control 
support was employed as the blank. 
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Isolation of polyclonal anti-HSA antibodies from anti-HSA goat se-
rum was performed by using HSA silica [17] or protein G Sepharose 
[18]. A 200 mg portion of lyophilized anti-HSA goat serum was dis-
solved in 2.0 mL of pH 7.4, 0.067 M potassium phosphate buffer and 
added to 4 mg of protein G Sepharose or 0.50 g of HSA silica, with the 
latter being prepared using Nucleosil Si-1000 silica and the Schiff base 
method [17]. The serum and support slurry were allowed to mix at 
room temperature for 2 h. The slurry was centrifuged at 7500 rpm for 
3 min and room temperature to separate the retained anti-HSA anti-
bodies from other serum components. The supernatant was decanted, 
and the support washed with 2.0 mL of the pH 7.4 buffer prior to an-
other centrifugation and decanting step. This step was repeated a to-
tal of three times. The retained anti-HSA antibodies were eluted from 
the protein G Sepharose or HSA silica by washing the support with 
three 1.0 mL portions of pH 2.5, 0.10 M potassium phosphate buffer, 
followed by a centrifugation step and recollection of the supernatant 
after each step. The pH of the collected anti-HSA antibodies was ad-
justed to pH 6.0 by adding pH 8.0, 0.10 M potassium phosphate buf-
fer. These antibodies were immobilized onto 1.0 g of Nucleosil 1000-7 
by the Schiff base method [17]. A control support was prepared in the 
same fashion but without any antibodies being included in the reac-
tion mixture. The protein content of the anti-HSA support was mea-
sured by using a BCA assay, as described earlier. 
The support made with the affinity-purified anti-HSA antibodies 
was packed into 1.0 cm × 2.1 mm I.D. stainless steel columns at 4000 
psi (27.6 MPa), with pH 7.4, 0.067 M potassium phosphate buffer be-
ing used as the packing solution. The anti-HSA support made from 
anti-HSA goat serum was packed in the same manner into 2.0 cm and 
5.0 cm × 2.1 mm I.D. columns (combined effective length, 7.0 cm). 
Control columns of the same sizes were also prepared in this man-
ner. The columns were stored in pH 7.4, 0.067 M potassium phos-
phate buffer at 4.0 °C. The binding capacity of each anti-HSA column 
was measured in triplicate by frontal analysis at 0.10 mL/min and by 
using a 5.0 μM solution of HSA in pH 7.4, 0.067 M potassium phos-
phate buffer at 37 °C. In this measurement, the active antibody con-
tent was determined by utilizing the difference in the midpoints of 
the breakthrough curves that were obtained on the anti-HSA column 
and a control column [18]. 
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2.4. Preparation of hydrazide-activated silica and oxidized glycogen 
Hydrazide-activated silica was prepared by using Nucleosil-300 silica 
as the starting material, which was first converted into a diolbonded 
form [8,19]. The diol-bonded silica was oxidized into an aldehyde 
form by using periodic acid, and hydrazide groups were incorporated 
by combining the aldehyde-activated silica with oxalic dihydrazide, 
as described previously [8,9]. Any remaining aldehyde groups on the 
support were reduced by using sodium borohydride [8,19]. The hydra-
zide-activated silica was stored at 4 °C in pH 7.0, 0.10 M phosphate 
buffer, conditions under which this support is stable for up to 6 weeks 
[19]. This support was packed into 1.0 cm × 2.1 mm I.D columns in 
the same manner as described in Section 2.3 for the anti- HSA sup-
ports. These columns were used within 24 h of being packed to mini-
mize any loss of hydrazide groups on the support prior to entrapment. 
Oxidation of glycogen was carried out by reacting 17 mg of bovine 
glycogen with 135 mg of periodic acid in 4.0 mL of pH 5.0, 20 mM ac-
etate buffer containing 15 mM sodium chloride [9]. The glycogen so-
lution was vortexed for 5 min, degassed for 5 min, and placed on a 
wrist shaker (set at 300 oscillations per min) for 16 h at room temper-
ature. The oxidized glycogen was purified by ultrafiltration, in which 
the oxidized glycogen solution was washed three times with water 
and three more times with pH 6.0, 0.10 M potassium phosphate buf-
fer. Each wash was followed by a centrifugation step that was per-
formed at 3000 rpm and 37 °C. The oxidized glycogen solution was 
removed from the ultrafiltration device with 4.0 mL of pH 6.0, 0.10 
M potassium phosphate buffer and used immediately in the entrap-
ment of HSA. 
2.5. Construction of immunoextraction/entrapment system 
The final immunoextraction/entrapment system used an effective 
anti-HSA column size of 8.0 cm × 2.1 mm I.D. (i.e., one 1.0 cm long 
column based on affinity-purified anti-HSA antibodies, plus 2.0 cm 
and 5.0 cm× 2.1 I.D. columns using anti-HSA antibodies from goat se-
rum), along with a 1.0 cm × 2.1 mm I.D. strong cation exchange (SCX) 
Biobasic guard column (Sigma-Aldrich, St. Louis, MO, USA). The SCX 
column was used to recapture HSA that was retained and eluted from 
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the immunoextraction columns and to place this protein into a buffer 
that could be used for entrapment. The elution of HSA during the de-
velopment and utilization of this system was monitored at 280 nm. 
In this final system, the anti-HSA immunoextraction columns were 
first equilibrated with pH 7.4, 0.067 M potassium phosphate buffer 
at 0.10 mL/min. The SCX column was equilibrated with pH 2.5, 0.10 
M potassium phosphate buffer at 0.50 mL/min. All of these columns 
were kept at 37 °C. A 20.0 μL sample containing HSA was injected at 
0.10 mL/min onto the immunoextraction columns in the presence of 
pH 7.4, 0.067 M potassium phosphate buffer. After 10 min, the re-
tained HSA was eluted at 0.10 mL/min by applying pH 2.5, 0.10 M 
potassium phosphate buffer. This elution was carried out for 25 min 
and was done with the immunoextraction columns connected on-line 
with the SCX column. The HSA that was captured by the SCX column 
was later eluted by using pH 6.0, 0.10 M potassium phosphate buffer 
at 0.50 mL/min. The HSA that was eluted from the SCX column was 
collected over a period of 55 s in an on-line 500 μL loop. 
The HSA collected in the loop was next entrapped within a 1.0 
cm×2.1 mm I.D. column that contained hydrazide-activated silica. 
This step was done by first passing the captured protein repeatedly 
through the column for 4 h at 20 μL/min by using two syringe pumps 
that were synchronized to withdraw and infuse the protein solution 
through the column [9,12]. The HSA solution was then combined man-
ually with an equal volume of a solution containing 4.25 mg/mL of ox-
idized glycogen; this mixture was circulated through the column for 
another 16–20 h. In the final step, 450 μL of pH 6.0, 0.10 M potas-
sium phosphate buffer containing 1.0 mg/mL oxalic dihydrazide was 
applied for 2 h to the column to cap any remaining active aldehyde 
groups on the oxidized glycogen. A control column was made the same 
way but with pH 6.0, 0.10 M phosphate buffer being used in place of 
the HSA solution. The columns were then washed with 30.0 mL of pH 
7.4, 0.067 M potassium phosphate buffer at 0.50 mL/min and stored 
in the same buffer at 4 °C. 
2.6. Chromatographic studies 
All injections onto the entrapped protein columns were made in trip-
licate at 0.25 or 0.50 mL/min and 37 °C in the presence of pH 7.4, 
0.067 M potassium phosphate buffer as the mobile phase. The injected 
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volume of the probe or drug solutions was 20 μL. A sample concentra-
tion of 10.0 μM for warfarin or L-tryptophan was used during optimi-
zation of the entrapment conditions in Section 3.4; a warfarin concen-
tration of 1.0 μM was used in Sections 3.5 and 3.6. The void volume 
was measured by injecting 5.0 μM sodium nitrate, which is a non-re-
tained solute for the types of columns and supports that were used in 
this study [20]. All sulfonylurea drugs were injected at a sample con-
centration of 1.0 μM except for glibenclamide, for which the sample 
concentration was 5.0 μM (Note: this was done to allow for good de-
tection of the broad and strongly-retained peak for glibenclamide). 
The following wavelengths were used for detection: acetohexamide, 
252 nm; glibenclamide, 290 nm; tolbutamide or glipizide, 226 nm; so-
dium nitrate, 205 nm; L-tryptophan, 280 nm; and warfarin, 308 nm. 
Serum was filtered prior to injection by using an Acrodisc PVDF sy-
ringe filter (0.2 μm pore size) from Waters (Milford, MA, USA). 
3. Results and discussion 
3.1. Characterization of immunoextraction columns 
The total antibody content for each immunoextraction support was 
measured by using a protein assay. The protein content when using the 
affinity-purified anti-HSA antibodies was 22.1 (±1.2) mg antibodies/g 
silica, and the protein content when using anti-HSA antibodies from 
goat serum was 18.0 (±0.1) mg antibodies/g silica when using HSA 
silica for purification or 30.5 (±1.4) mg antibodies/g silica when using 
protein G. The support made with the affinity-purified anti-HSA anti-
bodies was packed into a 1.0 cm × 2.1 mm I.D. column, while the sup-
port made using the anti-HSA antibodies from goat serum was packed 
into 2.0 cm and 5.0 cm × 2.1 mm I.D. columns (combined length, 7.0 
cm; using HSA silica and protein G for antibody purification, respec-
tively). The total antibody content of these columns, based on a mo-
lar mass for the antibodies of 150 kDa and a known packing density 
for the supports of 0.45 g/cm3, was 2.30 (±0.12) nmol or 35.2 (±1.2) 
nmol, respectively. 
The binding capacity of each column was determined by using fron-
tal analysis and solutions with known concentrations of HSA that were 
applied at 0.10 mL/min, pH 7.4 and 37 °C. The binding capacity for 
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the 1.0 cm × 2.1 mm column was 0.27 (±0.02) nmol HSA, while the 
binding capacities for the 2.0 cm and 5.0 cm × 2.1 mm columns were 
1.38 (±0.05) nmol HSA and 1.50 (±0.05) nmol HSA, respectively. By 
combining the data from the protein assays and frontal analysis, it 
was determined that 11.9 (±1.1)%, 36.9 (±0.1)% and 9.5 (±0.1)% of 
the immobilized antibodies were active and able to bind HSA within 
the 1.0 cm, 2.0 cm, and 5.0 cm long immunoextraction columns, re-
spectively. The 1.0 cm × 2.1 mm column containing affinity- purified 
anti-HSA antibodies was used in most of the following studies but was 
combined with the 2.0 cm and 5.0 × 2.1 mm anti-HSA columns to in-
crease the overall binding capacity in the final immunoextraction/ en-
trapment system (see Sections 2.5 and 3.5). 
3.2. Optimization of conditions for immunoextraction 
A 1.0 cm × 2.1 mm I.D. immunoextraction column was used to study 
the capture efficiency of HSA while varying the injection flow rate. 
This was done by injecting 20 μL of 10.0 μM HSA in pH 7.4, 0.067 M 
potassium phosphate buffer onto the column at 37 °C. The retained 
HSA was eluted at 37 °C using pH 2.5, 0.10 M potassium phosphate 
buffer. Elution was performed at pH 2.5 because this pH is known to 
effectively dissociate HSA from polyclonal antibodies without irrevers-
ibly affecting the structure of this protein or the antibodies [21–23]. 
This elution buffer was also chosen because it could act as a weak mo-
bile phase for an SCX column, thus allowing use of this latter column 
for the retention and re-concentration of HSA that was eluted from 
the immunoextraction column (see Section 3.3). 
In these experiments, the HSA was injected at flow rates ranging 
from 0.10 to 0.50 mL/min into the pH 7.4 application buffer of the 
immunoextraction column. After 10 min, the retained HSA was eluted 
at pH 2.5 and 0.10 mL/min, and the area of the eluted peak was mea-
sured. Injections using the same volume and concentration of HSA, but 
now in the presence of pH 2.5, 0.10 M phosphate buffer as the sample 
buffer and mobile phase, were made onto an inert control column to 
provide the total expected peak area. 
The results are summarized in Table 1. Almost 94% of the ap-
plied HSA was captured by a 1.0 cm × 2.1 mm I.D. immunoextrac-
tion column at 0.10 mL/min. The protein sample in this experiment 
contained 0.20 nmol HSA, which represented 74% of the measured 
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column binding capacity. For the same amount of sample, there was 
a small decrease of 6.6–7.3% (i.e., a difference significant at the 95% 
confidence level) when going from 0.10 to 0.25–0.50 mL/min. Thus, 
an application flow rate of 0.10 mL/min was used in all further work 
with the immunoextraction columns. Similar or higher capture effi-
ciencies would be expected for smaller amounts of applied HSA or 
columns with a higher binding capacity, such as the 2.0 cm plus 5.0 
cm × 2.1 mm immunoextraction columns that were used later in Sec-
tions 3.5–3.6 as part of the final immunoextraction/entrapment sys-
tem [21,22]. 
The backpressure and stability of the immunoextraction columns 
were also considered, as well as their ability to release the captured 
HSA. For a 1.0 cm × 2.1 mm I.D. immunoextraction column, the back-
pressure increased from 0.3 MPa (44 psi) at 0.10 mL/min to 1.1 MPa 
(160 psi) at 0.50 mL/min. A larger proportional change was noted for 
2.0 cm plus 5.0 cm × 2.1 mm I.D. immunoextraction columns, which 
gave an increase in backpressure of 1.7 MPa (247 psi) at 0.10 mL/min 
to 3.6 MPa (522 psi) at 0.25 mL/min. 
The stability of the combined immunoextraction columns and their 
release of captured HSA were monitored by comparing the peak area 
of the retained HSA after each injection for a standard sample of this 
protein (i.e., 20 μL of 10.0 μM HSA). After 48 injections there was a 
decrease of only 10% in the retained peak area (or ~ 0.2% per appli-
cation of HSA). This small decrease may have been due to a slow loss 
of activity in the anti-HSA antibodies over time, or a small level of 
carryover of non-eluted HSA. The gradual loss of column binding ca-
pacity was not a major issue in this study because the retained peak 
Table 1 Degree of capture and rate of elution of retained HSA at various flow rates when using 
a 1.0 cm × 2.1 mm I.D. anti-HSA immunoextraction column.a
Flow rate  Retained HAS Dissociation rate constant 
(mL/min)  at pH 2.5 (×10−3 s−1)
0.10  93.8 (±1.4)%  3.8 (±0.1)
0.25  86.5 (±1.0)%  4.4 (±0.1)
0.50  87.2 (±1.0)%  5.9 (±0.2)
a. The values in parentheses represent a range of±1 S.D. (n = 3). The dissociation rate con-
stants were obtained by fitting the natural logarithm of the elution peak at pH 2.5 and the 
given flow rate to Eq. (1), as described in the text.
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area was used to monitor and correct for the amount of HSA that was 
passed onto the rest of the system for capture by SCX or for use in 
entrapment. 
The time needed to elute the captured HSA from an immunoex-
traction column at pH 2.5 was next studied. This was done by using a 
20 μL sample of 630 μM HSA (i.e., 42 g/L HSA, a typical serum con-
centration of this protein; total injected HSA, 12.6 nmol) to saturate 
a set of coupled immunoextraction columns (i.e., the 1.0 cm and 2.0 
cm plus 5.0 cm × 2.1 mm I.D. columns) with a combined binding ca-
pacity for HSA of 3.15 (±0.07) nmol. The HSA sample was injected 
at 0.10 mL/min and 37 °C in the presence of pH 7.4, 0.067 M potas-
sium phosphate buffer, followed by a 10 min wash at pH 7.4 and elu-
tion of the retained HSA at 0.10 mL/min using pH 2.5, 0.10 M phos-
phate buffer. A similar study was carried out by applying 20 μL of 10 
μM HSA at 0.10 mL/min to a 1.0 cm×2.1 mm I.D. anti-HSA column to 
examine the elution profile when an immunoextraction column was 
not fully saturated with HSA (i.e., conditions using 74% of the avail-
able binding capacity). 
The profile of the eluting peak was examined by peak decay analy-
sis [24–27]. This was done by employing Eq. (1) to determine the dis-
sociation rate constant (kd) for HSA as it was released from an immu-
noextraction column [25]. 
ln(dmAe ) = ln (kd mA0 ) – kd t                 (1) 
       dt
In this equation, mA0 represents the moles of HSA (or analyte, A) that 
were initially bound to the column, and mAe is the moles of A that 
eluted at time t. This equation indicates that a plot of the natural 
logarithm of the elution peak versus time for a process that follows 
pseudo-first order dissociation (i.e., as is often present during the elu-
tion of analytes from immobilized antibodies) should result in a lin-
ear response with a slope equal to –kd [25]. 
Fig. 3 shows some typical results that were obtained when Eq. (1) 
was fit to the elution profile for HSA when the combined 1.0 cm and 
2.0 cm plus 5.0 cm × 2.1 mm I.D. immunoextraction columns were 
saturated with this protein. A relatively broad elution peak was seen 
for HSA from these columns, as shown in Fig. 3(a) and has been noted 
for other systems based on immunoextraction [22,27]. The integrated 
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form of the peak, as shown in Fig. 3(b), indicated that>99% of the 
HSA eluted in 15.2 min at 0.10 mL/min and>99.9% eluted in 18.0 min. 
Based on these results, elution was allowed to occur for at least 18 min 
and up to 25 min in all later experiments in this study. The logarith-
mic transform of this peak profile gave a reasonably good fit with Eq. 
(1) and a first-order decay model at times of 1.7 min or greater at 0.10 
Fig. 3. (a) Elution of HSA from a set of immunoextraction columns (1.0 cm and 
2.0 cm plus 5.0 × 2.1 mm I.D. anti-HSA columns connected in tandem) at 0.10 mL/
min and 37 °C in the presence of pH 2.5, 0.10 M phosphate buffer and (b) the rel-
ative amount of HSA eluted versus time under these conditions. The time scale be-
gins at the point at which the elution buffer was applied to the immunoextraction 
columns (i.e., 10 min after the initial injection of HSA). The chromatograms have 
been corrected for the background response obtained when no HSA was present. 
The inset in (b) shows the logarithmic transform of the elution peak and the linear 
region of this plot, as determined according to Eq. (1) and described by the best-fit 
line y = -0.2494 × + 12.49 (correlation coefficient, 0.9814). Abbreviations: Au, ab-
sorbance units.  
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mL/ min, as shown by the inset of Fig. 3. The slope for this fit gave an 
estimated dissociation rate constant between HSA and the anti-HSA 
antibodies of 4.2 (±0.1) × 10−3 s−1 at pH 2.5 and 37 °C. Similar disso-
ciation rate constants of 3.8–4.4 × 10−3 s−1 were obtained over compa-
rable elution times and at 0.10 or 0.25 mL/min when a nonsaturating 
amount of HSA was applied to a 1.0 cm × 2.1 mm I.D. immunoextrac-
tion column (see Table 1). 
3.3. Optimization of conditions for strong cation-exchange 
The flow rate and pH conditions to be used with a small SCX col-
umn to capture and elute HSA were next considered. In these exper-
iments, 20 μL of 2.5 μM HSA (or 0.05 nmol) in pH 2.5, 0.10 M po-
tassium phosphate buffer was injected onto a 1.0 cm × 2.1 mm I.D. 
SCX column. These injections were made in the presence of pH 2.5, 
0.10 M potassium phosphate buffer at 0.10 mL/min and 37 °C (i.e., 
the same conditions selected in the previous section for eluting HSA 
from the immunoextraction columns). Under these injection and ap-
plication conditions, an average of 95.5 (±1.4)% HSA was retained by 
the SCX column. 
The effect of altering the pH of the SCX elution buffer was next 
considered. The isoelectric point (pI) of HSA is 4.7. This means the 
overall charge of HSA at a pH higher than 4.7 will be negative [1,21], 
with elution of this protein becoming easier from a negatively-
charged SCX column as the pH is increased to 5.0 or higher. In addi-
tion to the pH of 5.0 that was initially employed, elution buffers with 
a pH of 6.0 or 7.0 were also examined. This work was done at an elu-
tion flow rate of 0.25 mL/min and 37 °C. As shown in Fig. 4(a), pH 
5.0 gave the broadest elution profile for HSA from the SCX column, 
with narrower elution profiles being obtained at pH 6.0 and 7.0. For 
instance, increasing the mobile phase pH from 5.0 to 6.0 or 7.0 at 
0.25 mL/min resulted in 2.0- to 2.5-faster elution of HSA from the 
SCX column. An elution pH of 6.0 was selected for later use in this 
report due to its ability to quickly elute HSA from the SCX column 
and its compatibility with the conditions that were needed for en-
trapment, as discussed in Section 3.4. 
The elution flow rates and times that could be used to remove and 
collect HSA from the SCX column were examined. The backpressure of 
the SCX column at pH 6.0 ranged from only 0.4 MPa (58 psi) at 0.10 
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mL/min to 1.3 MPa (188 psi) at 0.50 mL/min. All of these backpres-
sures were acceptable for use in this report. Fig. 4(b) shows the elu-
tion profile of HSA from the SCX column that was obtained at 0.50 
mL/min and pH 6.0, following application of a 20 μL solution contain-
ing 42 g/L HSA onto the immunoextraction columns, and capture of 
the retained HSA by the SCX column, as described in the previous sec-
tion. The resulting elution peak was similar in shape to those shown 
in Fig. 4(a) at 0.25 mL/min, but with the peak maximum at 0.50 mL/
Fig. 4. (a) Elution of HSA from a 1.0 cm × 2.1 mm I.D. SCX column at 0.25 mL/min 
and at pH 5.0, 6.0 or 7.0 and (b) the relative amount of HSA eluted versus time 
from the SCX column at pH 6.0 and 0.50 mL/min, where the inset shows the orig-
inal elution profile. The time scale begins at the point at which the elution buffer 
was applied to the SCX column (i.e., 35 min after injection of HSA onto the immu-
noextraction columns). The chromatograms have been corrected for the background 
response obtained when no HSA was present. Abbreviations: Au, absorbance units. 
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min appearing at a proportionately shorter time. As shown in Fig. 
4(b), 95% of this peak eluted within 25 s at 0.50 mL/min and 99% 
eluted within 46 s (i.e., elution volumes of ~ 208 and 380 μL, respec-
tively). As this peak eluted, it was collected by passing the SCX col-
umn eluent through an on-line 500 μL loop. This collection occurred 
over the first min of elution from the SCX column, or between 35 and 
36 min after the original injection of the HSA sample onto the immu-
noextraction column (i.e., a time over which>99.7% of the HSA was 
eluted). Based on this information and the results in Fig. 4, an elu-
tion pH of 6.0 and flow rate of 0.50 mL/min for the SCX column were 
used in all further studies in this report. 
3.4. Optimization of conditions for entrapment 
Protein entrapment by the method shown in Fig. 1 is normally per-
formed at pH 5.0 to allow hydrazide groups on the support to react 
with oxidized glycogen and entrap a protein such as HSA [8–12]. How-
ever, other pH values that are above or below 5.0 may also be used for 
this process [19]. In the previous section it was determined that pH 
6.0, 0.10 M phosphate buffer was effective in releasing HSA from the 
SCX column. Because this pH was higher than the value of 5.0 that is 
often used for entrapment [8–12], the effect of using pH 6.0 for the 
entrapment of HSA was next examined. A 300 μL portion of a solu-
tion containing 100 mg/mL HSA in pH 6.0, 0.10 M phosphate buffer 
was first infused and withdrawn through a 1.0 cm × 2.1 mm I.D. col-
umn containing hydrazide-activated silica, according to conditions 
given in Section 2.5 and used previously at pH 5.0 [9]. This was fol-
lowed by the infusion and withdrawal of an equal volume mixture of 
4.25 mg/mL oxidized glycogen and 100 mg/mL HSA in pH 6.0 buffer, 
0.10 M phosphate buffer, and then capping of any remaining aldehyde 
groups (i.e., as described in Section 2.5) [9]. For comparison, a col-
umn containing entrapped HSA was prepared in the same manner but 
using pH 5.0, 20 mM acetate buffer containing 15 mM sodium chlo-
ride. Control columns were also prepared at pH 6.0 and pH 5.0 with 
no HSA being applied during the entrapment process. 
The protein content of each column was determined by means of 
zonal elution and using warfarin and L-tryptophan as probe com-
pounds [17,28]. Warfarin is known to bind at Sudlow site I of HSA 
and L-tryptophan binds at Sudlow site II with association equilibrium 
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constants of 2.4 × 105 M−1 [17] and 1.1 × 104 M−1 [28], respectively, at 
pH 7.4 and 37 °C. The moles of active protein (mL) in each entrapped 
HSA column was estimated by using Eq. (2) and the measured reten-
tion factor (k) for a given probe compound [29]. 
k = Ka mL                                 (2) 
          Vm
In this equation, Ka is the association equilibrium constant for the 
probe with HSA, and Vm is the column void volume (i.e., as determined 
by injecting sodium nitrate as a non-retained solute). Based on this 
relationship, the HSA contents of the columns made at pH 5.0 and 6.0 
were determined to be 19.5 (±1.3) nmol and 14.6 (±0.7) nmol, respec-
tively. A decrease of about 25% in HSA content occurred when using 
pH 6.0 instead of 5.0 for entrapment, a difference that was signifi-
cant at the 95% confidence level; however, these results did indicate 
that pH 6.0 could still be effectively used for the entrapment process. 
Thus, pH 6.0 was used as both the elution pH for the SCX column and 
as the pH for the entrapment process in the remainder of this report. 
3.5. Preparation of HSA columns using immunoextraction/
entrapment system 
The final immunoextraction/entrapment system, as based on the con-
ditions selected in Sections 3.1–3.4, was first tested for use in prepar-
ing small columns for drug binding studies by using a sample that 
contained a commercial sample of purified HSA. This sample was pre-
pared in pH 7.4, 0.067 M phosphate buffer at a physiological concen-
tration of HSA (42 g/L). A 20 μL injection of this HSA solution was 
made onto the system, and the captured HSA was entrapped within 
a 1.0 cm×2.1 mm I.D. hydrazide-activated silica column in the pres-
ence of oxidized glycogen. A control column was prepared in a simi-
lar manner off-line and with no HSA being applied. The protein con-
tent of the entrapped HSA column was again determined by using Eq. 
(2) and injecting warfarin as a probe compound with known binding 
properties for HSA [17]. The protein content of the column was found 
in this manner to be 0.56 (±0.10) nmol HSA. 
The entrapped HSA column was employed to measure the global 
affinity constants (nKa) [10–13] for HSA with several sulfonylurea 
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drugs: acetohexamide, glibenclamide, glipizide and tolbutamide. 
These drugs have been used in the management of glucose levels in 
blood in diabetic patients and have global affinity constants for HSA 
that have been measured in prior studies [13–16]. All of these drugs 
were injected in triplicate at 0.25 mL/min and 37 °C using pH 7.4, 
0.067 M phosphate buffer as the mobile phase (i.e., the same tem-
perature, pH and buffer conditions as used in prior binding studies 
in Refs. [13–16]). The same drugs and conditions were used on a con-
trol column to detect and correct for any non-specific interactions of 
these drugs with the support. Fig. 5 shows some typical chromato-
grams that were obtained in these studies, with results being ac-
quired for most of the drugs within 3.0 min of injection at 0.25 mL/
min. The only exception was glibenclamide, which had the strongest 
binding and highest retention on the HSA column and which eluted 
within about 8 min. 
Fig. 5. Retention noted for samples of (a) 1.0 μM acetohexamide or (b) 5.0 μM glib-
enclamide that were injected onto a 1.0 cm × 2.1 mm I.D. entrapped HSA column or 
control column in the presence of pH 7.4, 0.067 M potassium phosphate buffer at 
0.25 mL/min and 37 °C. Abbreviations: Au, absorbance units.  
Rodriguez  et  al .  in  Journal  of  Chromato graphy  B  1 136  (2020)        19
The retention factors measured for the sulfonylurea drugs on the 
HSA and control columns are summarized in Table 2. The specific 
retention factor for each drug due to HSA was obtained by subtract-
ing the retention factor for the drug on the control column from that 
measured on the HSA column. The non-specific interactions of these 
drugs with the support, as determined by comparing their retention 
on the HSA and control columns, accounted for only 1–21% (average, 
10%) of the total retention factors measured on the HSA column. The 
specific retention factors measured for these drugs had precisions of 
± 9.5–13% (average,±11%).  
The global affinity constants that were calculated from these results 
are shown in Table 3. The precision of these values ranged from ± 
16–18% (average,±17%). The corresponding global affinity constants 
that were measured for the HSA that was applied in buffer spanned 
Table 3 Global affinity constants obtained for representative sulfonylurea drugs using 1.0 cm 
× 2.1 mm I.D. columns containing entrapped HSA.a
Drug  Global affinity constant (M−1)a
 Entrapment using  Entrapment using  Literature value 
 purified HSA  human serum  [Ref.]
Acetohexamide  1.75 (±0.31) × 105  1.67 (±0.22) × 105  1.7 (±0.1) × 105 [13]
Glibenclamide  1.98 (±0.35) × 106  2.56 (±0.29) × 106  2.11 (±0.47) × 106 [14]
Glipizide  2.03 (±0.33) × 105  2.27 (±0.22) × 105  2.57 (±0.80) × 105 [15]
Tolbutamide  1.22 (±0.22) × 105  1.27 (±0.15) × 105  1.08 (±0.03) × 105 [16]
a. The values shown in parentheses represent a range of ± 1 S.D. (n = 3). All global affinity 
constants were measured at pH 7.4 and 37 °C.
  
Table 2 Retention factors measured for various sulfonylurea drugs on a 1.0 cm × 2.1 mm I.D. 
entrapped HSA column and control column.a
Drug  Retention factor  Retention factor Specific retention 
 on control column on HSA column factor due to HSAb
Acetohexamide  0.60 (±0.07)  3.47 (±0.36)  2.87 (±0.37)
Glibenclamide  8.71 (±0.99)  41.2 (±2.9)  32.4 (±3.1)
Glipizide  0.02 (±0.02)  3.35 (±0.35)  3.33 (±0.35)
Tolbutamide  0.02 (±0.01)  2.01 (±0.82)  1.99 (±0.26)
a. The values in parentheses represent a range of ± 1 S.D. (n = 3).
b. The specific retention factor due to HSA represents the difference between the retention 
factors that were measured for a drug in the presence of entrapped HSA and on the con-
trol column in the absence of any HSA. The values in parentheses for these results were 
determined by error propagation.
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from 1.22 to 19.8 × 105 M−1. These global affinities were consistent with 
those that have been previously reported for the same drugs with HSA 
under equivalent pH and temperature conditions [13–16]. These val-
ues were all equivalent to those from the literature at the 95% confi-
dence level. The results indicated that the immunoextraction/entrap-
ment system could be used to make HSA columns for binding studies 
and that these columns could be effectively used in the rapid deter-
mination of a drug’s overall affinity for HSA. 
3.6. Preparation of entrapped HSA columns from serum 
The system was also used to entrap HSA from serum. This was per-
formed by filtering the serum and mixing it 1:1 with pH 7.4, 0.067 M 
phosphate buffer. This mixture was then applied to the immunoex-
traction/ entrapment system and used to entrap the captured HSA in 
a 1.0 cm × 2.1 mm I.D. column, as described in Section 3.5. It was de-
termined by using Eq. (2) and injecting warfarin as a probe that 0.35 
(±0.08) nmol of HSA from the diluted serum was entrapped by this 
method. 
The global affinity constants for acetohexamide, glibenclamide, 
glipizide, and tolbutamide were again determined, but now using the 
entrapped HSA column that was prepared from serum. The results are 
included in Table 3. These results were again equivalent at the 95% 
confidence level to those reported in the literature [13–16]. Similar 
agreement was seen with the values obtained in Section 3.5 when us-
ing an entrapped HSA column that was prepared from commercial, 
purified HSA. The precisions of the global affinities obtained when us-
ing entrapped HSA from serum were±9.7–13.6% (average,±11.6%), 
which were similar to the precisions seen in Section 3.5 for columns 
made through the entrapment of purified HSA. 
The stabilities of both the columns made from serum and puri-
fied HSA were also examined. No significant variations, at a 95% 
confidence level, were observed in the retention times of drugs that 
were injected over the course of two weeks on either type of column. 
This level of stability was seen over at least 60 injections on a col-
umn containing purified HSA (as observed over several applications 
of fresh portions of HSA) and a similar value of over 54 injections on 
a column made from serum. The combined results indicated that the 
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immunoextraction/entrapment system could be used to capture and 
isolate a protein like HSA from a solution or a sample such as serum 
and to place this protein into a column for use in HPAC and multiple 
drug binding studies. 
4. Conclusion 
In this study a system was developed that could purify, extract and en-
trap HSA within small affinity columns. The system utilized an immu-
noextraction column containing polyclonal anti-HSA antibodies that 
could extract HSA from either aqueous samples or serum. The immu-
noextraction column was used in tandem with a SCX column to con-
centrate the captured HSA and place it into a buffer that had a suit-
able pH for entrapment. The entrapment of HSA was performed on 
this system by using a hydrazide-activated column and oxidized gly-
cogen as a capping agent. The 1.0 cm × 2.1 mm I.D. HSA columns that 
were created by this system had a typical protein content of 0.3–0.6 
nmol. These columns were stable over several weeks and more than 
50–60 sample injections when used in drug binding studies. 
The HSA columns created by using this system were used to mea-
sure the global affinity constants for HSA with various sulfonylurea 
drugs. These binding constants could be determined in a matter of 
minutes, had precisions of around ±10–18%, and gave good agree-
ment with literature values. A potential future application of this sys-
tem is in the field of personalized medicine. For instance, small HSA 
columns could be developed by using individual serum samples to 
examine drug interactions with the entrapped protein to aid in pa-
tient treatment [30]. This would include work with both normal HSA 
and glycated forms of HSA, which have been shown to have equiva-
lent binding to the types of polyclonal anti-HSA antibodies that were 
employed in this study [30]. Given the strong and selective binding 
of antibodies when used in affinity columns [31,32], the same type of 
system as used here for HSA could also be adapted in future work to 
capture and entrap other, lower-abundance proteins for binding stud-
ies or related applications by employing alternative antibodies against 
the given target for immunoextraction.   
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Supplemental Material  
Figure S1 shows the valve configuration and valve positions that were 
used to control the flow of applied solutions and mobile phases in the 
immunoextraction/entrapment system. Valve 1 was used to control 
the injection buffer and elution buffer for the immunoextraction col-
umn. In position A, the sample was injected into the column, and in 
position B the retained HSA was eluted onto a strong cation-exchange 
(SCX) column. Valve 2 controlled the mobile phase that was used in 
the SCX column. In position A, HSA that was eluted from the immu-
noextraction column was retained by the SCX column and in position 
B the retained HSA in the SCX was eluted. Valve 3 was used to cap-
ture the HSA that was eluted from the SCX column. In position B, this 
valve collected the eluted HSA in a 500 μL loop; in position A, the cap-
tured HSA was passed through the entrapment column. 
Rodriguez  et  al .  in  Journal  of  Chromato graphy  B  1 136  (2020)        25
Figure S1. Valve configurations and positions used to control solution and mobile 
phase flow in immunoextraction/entrapment system.
